Search
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. … It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. … [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]
Pain caused by Fracture Bone
go.drugbank.com/conditions/DBCOND0135073Synonyms: Pain caused by Fracture BoneAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalIt is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC … Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigational[L44381] It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS) … Most patients with this condition undergo radical cystectomy since other non-surgical treatments are far less effective.
Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalApproved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion. … Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype.
Oxaprozin
go.drugbank.com/drugs/DB00991ApprovedOxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticNomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnApproval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets. … The approved application holder removed Merital capsules from the market on January 23, 1986.
Zomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnThe manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSTechnetium Tc-99m medronate
go.drugbank.com/drugs/DB09138ApprovedInvestigationalLike other bisphosphonates used in the treatment of osteoporosis, medronic acid binds to the hydroxyapatite crystals within bone, and in this way localizes the drug to bone for delineation of areas of … It is composed of a technetium ion complexed with medronic acid, a type of bisphosphonate.